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Abstract
Liver cancer is a complex multistep process requiring genetic alterations in multiple proto-oncogenes and tumor suppressor
genes. Although hundreds of genes are known to play roles in hepatocarcinogenesis, oncogenic collaboration among these
genes is still largely unknown. Here, we report a simple methodology by which oncogenic cooperation between cancer-
related genes can be efficiently investigated in the liver. We developed various non-germline transgenic mouse models
using hydrodynamics-based transfection which express HrasG12V, SmoM2, and a short-hairpin RNA down-regulating p53
(shp53) individually or in combination in the liver. In this transgenic system, firefly luciferase was co-expressed with the
oncogenes as a reporter, allowing tumor growth in the liver to be monitored over time without an invasive procedure. Very
strong bioluminescence imaging (BLI) signals were observed at 4 weeks post-hydrodynamic injection (PHI) in mice co-
expressing HrasG12V and shp53, while only background signals were detected in other double or single transgenic groups
until 30 weeks PHI. Consistent with the BLI data, tumors were observed in the HrasG12V plus shp53 group at 4 weeks PHI,
while other transgenic groups failed to exhibit a hyperplastic nodule at 30 weeks PHI. In the HrasG12V plus shp53
transgenic group, BLI signals were well-correlated with actual tumor growth in the liver, confirming the versatility of BLI-
based monitoring of tumor growth in this organ. The methodology described here is expected to accelerate and facilitate
in vivo studies of the hepatocarcinogenic potential of cancer-related genes by means of oncogenic cooperation.
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Introduction
Liver cancer is a complex multistep process that involves genetic
alterations in multiple proto-oncogenes and tumor suppressor
genes [1–3]. Hundreds of genes are known to play roles in the
initiation and progression of hepatocellular carcinoma (HCC) after
having undergone a genetic alteration [3,4]. An oncogenic
mutation in a single gene, however, usually fails to induce liver
cancer, as shown in transgenic mouse models expressing single
oncogenes [5,6]. This implies that oncogenic collaboration among
multiple cancer-related genes is required to induce HCC.
Identifying oncogenes that cooperatively induce HCC will
facilitate a greater understanding of the genetic mechanism(s)
underlying liver carcinogenesis and will provide new insights into
the genetic pathway that leads to HCC.
Ras proteins are the prototype 21-kDa GTPases and serve as
master regulators in a myriad of signaling cascades. An activating
mutation in ras genes (a mutation at codon 12 resulting in the
substitution of valine for glycine, for example) leads to constitutive
activation of the Ras signaling pathways. An activation of the Ras
signaling pathways is found in more than 50% of HCCs [7,8].
Another pathway that is frequently activated in HCC is the
hedgehog signaling pathway, which is closely related to cell cycle,
proliferation, and angiogenesis. An activating mutation in Smo
(such as a mutation at codon 535 leading to substitution of leucine
for tryptophan) causes hedgehog signaling to be constitutively
active and is found in a variety of tumors [9,10]. The p53 pathway
is a major tumor-suppressing signaling pathway that limits cell
survival and induces cell-cycle arrest. Loss of p53 function is
frequently found in tumors of diverse cellular origins, including
HCC, and is considered a critical step in tumor development
[1,11].
To better understand the roles of genetics in HCC develop-
ment, genetically modified mouse (GEM) models in which
expression of a specific oncogene or tumor suppressor gene is
manipulated have been developed [5,6]. The development of a
GEM model, however, usually involves expensive and time-
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consuming processes, thus generation of a variety of GEM models
is highly challenging.
Non-germline GEM models utilize transfection or transduction
of specific target tissues with vectors expressing a gene of interest
[12]. This approach can significantly reduce the time and
resources needed to generate transgenic models and is thus
suitable for testing the biological functions of various genes in a
relatively short time period in vivo. Applying the non-germline
transgenic approach, Zender et al. developed transgenic models of
HCC by ex vivo transduction of embryonic hepatoblasts with
retroviruses expressing various oncogenes, followed by transplan-
tation of the transduced hepatoblasts into the liver [13]. In another
very elegant and simple method, naked DNA plasmids encoding a
gene of interest are directly delivered into the liver by hydrody-
namics-based transfection [14]. For stable gene expression, the
transfection method has been coupled with the Sleeping Beauty
transposon system, which mediates chromosomal integration of a
transgene [15–17]. In this transgenic system, the expression
cassette of a transgene is placed between two inverted terminal
repeats (IRs), rendering the expression cassette transposable by
Sleeping Beauty transposase. To achieve stable expression of a
transgene, the transposon plasmids are hydrodynamically injected
together with plasmids expressing Sleeping Beauty transposase,
which excises the DNA regions flanked by the IRs and
subsequently transfers them to chromosomes.
One methodological challenge in studies using animal models of
HCC is that liver tumors are hard to observe due to the limitations
in access to the organ and in vivo imaging techniques. Genes
encoding fluorescent proteins or luciferases have been used to label
tumor cells in xenograft cancer models, allowing growth of
transplanted tumors to be observed by in vivo fluorescence or
bioluminescence imaging (BLI) [18,19]. The reporter genes have
also been used in GEM models for tumor imaging; however, the
additional genetic manipulation involved in expression of a
reporter gene makes the use of a reporter unattractive.
Here, we report a method by which oncogenic collaboration of
various cancer-related genes in the liver can be easily investigated
in vivo by BLI of tumors. Using firefly luciferase as a reporter,
tumor growth in the liver induced by a combination of oncogenes
was successfully monitored over time without an invasive
procedure.
Materials and Methods
Plasmids
The plasmid pCX-EGFP, which encodes enhanced green
fluorescent protein (EGFP), was a generous gift from Dr. Masaru
Okabe [20]. The whole expression cassette containing the chicken
b-actin promoter, EGFP cDNA, and a rabbit b-globin polyade-
nylation signal was cloned into pT2/BH (a kind gift from Dr.
Perry Hackett [21]), which has multiple cloning sites flanked by
the IRs. The resulting plasmid is referred to as pT2/EGFP. A
cDNA encoding an activated form of human Hras (HrasG12V)
was PCR amplified from pBABE puro H-Ras V12 (plasmid
#9051; Addgene) as a template using the following primer pair:
forward, 59-TTG AAT TCG CCA CCA TGA CGG AAT ATA
AGC TGG TGG TGG-39; and reverse, 59-TTG AAT TCT TAG
GAG AGC ACA CAC TTG C-39. The amplified products were
then digested with EcoRI and cloned into pT2/EGFP following
digestion of the plasmid with the same restriction enzyme to
remove the EGFP cDNA. The resulting plasmid is referred to as
pT2/HrasG12V. A cDNA encoding an activated form of Smo was
PCR amplified from pRK-SmoM2 as a template using the
following primer pair: forward, 59-TTG AAT TCG CCA CCA
TGG CCG CTG GCC GCC CCG TG-39; and reverse, 59-TTG
AAT TCT TAG AAG TCC GAG TCT GCA TC-39. The
amplified products were cloned into pT2/EGFP using the es
described above. The resulting plasmid is referred to as pT2/
SmoM2. pT2/shp53/GFP4, a transposon vector encoding a short
hairpin RNA against tumor suppressor p53, was a gift from Dr.
John Ohlfest and is hereafter referred to as pT2/shp53 [22]. The
plasmid PT2/C-Luc//PGK-SB13, which encodes Sleeping Beauty
transposase under the control of the phosphoglycerate kinase
(PGK) promoter and harbors a transposon expressing firefly
luciferase, was a kind gift from Dr. John Ohlfest.
Transfection, Western Blotting, and Gli-induced Firefly
Luciferase Expression Assays
NIH3T3 cells (CRL-1658; ATCC, Manassas, USA) were
transiently transfected with 2 mg of DNA using FuGENE HD
(Promega) according to the manufacturer’s instructions. For
detection of downstream Ras pathway molecules, cells were
harvested at 2 days post-transfection and lysed in 16RIPA buffer
(#9806; Cell Signaling). To evaluate the down-regulation of p53
expression by pT2/shp53, cells were transfected with pT2/EGFP
(as a control) and pT2/shp53, and were irradiated with UVC
(10 mJ/cm2) at 24 h post-transfection using an XL-1500 UV-
crosslinker (Spectronics Corporation). Cells were lysed in 16
RIPA buffer at 8 h post-irradiation. Western blotting experiments
were performed using standard methods. The following primary
antibodies were purchased from Cell Signaling Technology: anti-
p53 (#2524), anti-Akt (#9272), anti-phospho-Akt (#4060), anti-
ERK1/2 (#9102), anti-phospho-ERK1/2 (#4370), anti-MEK1/2
(#9126), and anti-phospho-MEK1/2 (#9154). For internal
controls, an anti-b-actin antibody (sc-47778, Santa Cruz) was
used. Anti-mouse IgG HRP (sc-2005, Santa Cruz) and anti-rabbit
IgG HRP (A0545, Sigma) were used as secondary antibodies. To
evaluate activation of hedgehog signaling by pT2/SmoM2, cells
were transfected with DNA mixtures containing 1 mg of pT2/
SmoM2, 100 ng of a plasmid encoding Renilla luciferase (as a
reference), and 1 mg of reporter plasmid (8639Gli-BS Luc carrying
binding sites for Gli transcription factors, a gift from Dr. Hiroshi
Sasaki) [23]. As a control, cells were transfected with DNA
mixtures containing 1 mg of pT2/EGFP, 100 ng of a plasmid
encoding Renilla luciferase, and 1 mg of the reporter plasmid.
Luciferase activity was measured with the dual luciferase reporter
assay system (Promega) according to the manufacturer’s instruc-
tions.
Animals
All experiments using live mice were performed in strict
accordance with the Guidelines and Regulations for the Care
and Use of Laboratory Animals in AAALAC-accredited facilities,
and were approved by the Animal Policy and Welfare Committee
of the Yonsei University College of Medicine (Permit number:
2011-0250). Male 5- to 6-week-old C57BL/6 mice were purchased
from Orientbio (Seongnam, Korea).
Hydrodynamic Injection
Hydrodynamic injection was performed as described previously
[14]. The plasmids pT2/HrasG12V, pT2/SmoM2, pT2/shp53,
and PT2/C-Luc//PGK-SB13 were prepared with endotoxin-free
Maxi Kits (Qiagen, Hilden, Germany). For the generation of
HrasG12V transgenic mice, 25 mg of pT2/HrasG12V (6.6 kb)
was mixed with 18.7 mg of PT2/C-Luc//PGK-SB13 (9.8 kb) such
that the molar ratio of transposon plasmids expressing an
oncogene to transposase-encoding vector was 2:1. The plasmid
Liver Cancer Models to Study Oncogenic Cooperation
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pT2/HrasG12V was used as the molar standard for transposons.
Mice of the same body weight each received the same molar
amount of transposons, regardless of the types of transposons. For
double transgenic groups, half-molar amounts of transposons for
each transgene were mixed together; i.e., 12.5 mg of pT2/
HrasG12V and 16 mg of pT2/SmoM2 (8.4 kb) were used to
generate HrasG12V plus SmoM2 double transgenic mice. After
mixing transposons with the transposase-encoding plasmids, DNA
was suspended in 2 ml of lactated Ringer’s solution and was then
injected into the lateral tail veins of male 6- to 7-week-old C57BL/
6 mice (0.1 ml/g body weight) in less than 7 sec.
Bioluminescence Imaging
The abdominal area of skin was depilated using a depilatory
cream 1 day before imaging. On the day of imaging, mice were
intraperitoneally injected with D-luciferin (150 mg/kg) and were
placed in a light-tight mouse imaging chamber following
anesthesia. A photographic (gray-scale) reference image was
obtained at 10 min after the administration of D-luciferin and
bioluminescence images were captured immediately thereafter.
Images were obtained with a CCD camera cooled to 290uC,
using the IVIS Imaging System (Caliper Life Sciences, Alameda,
CA, USA). Regions of interest were drawn in the abdominal
area and total counts (photons) in all areas were summed. The
signal intensities of each defined region of interest were
quantified as photon count rate per unit body area per unit
Figure 1. Schematic illustration of the experimental procedure. The transposons were mixed with the plasmids encoding the Sleeping Beauty
(SB) transposase and were then hydrodynamically delivered to the liver (see the Materials and Methods section). Once in cells, the SB transposase is
expressed and binds to the IR/DRs of the transposons. The enzyme subsequently cleaves the transposons at the sites of IR/DRs and integrates them
at a new location within the host genome, allowing the transgenes to be stably expressed. Mice are then subjected to repeated bioluminescence
imaging over time.
doi:10.1371/journal.pone.0059869.g001
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solid angle subtended by the detector (photons/s/cm2/steradi-
an).
Liver Harvesting, Tissue Processing, and H&E Staining
After euthanizing mice, their livers were removed and rinsed
in PBS. Samples collected from the livers were fixed overnight
in freshly prepared neutral-buffered formalin. Fixed tissue
samples were embedded in paraffin. Five-micron sections were
placed on slides and stained with hematoxylin and eosin (H&E)
in order to observe cell morphology. For immunofluorescence,
unfixed tissues were embedded in OCT and were then frozen.
Immunofluorescence
OCT-embedded frozen tissues were sectioned to a thickness of
5 mm using a cryostat microtome (Microm HM525; Thermo
Fisher Scientific, Walldorf, Germany). Each section was placed
on a slide and was subsequently fixed in acetone. Slides were
washed with phosphate-buffered saline (PBS) and blocked for
30 min at room temperature with PBS containing 1% goat
serum and 5% fetal bovine serum. The slides were then
incubated at room temperature for 1 h with a rabbit anti-Ras
antibody (sc-68743; Santa Cruz) diluted 1:100 in blocking buffer.
After washing, the slides were incubated at room temperature for
1 h with an Alexa 594-conjugated goat anti-rabbit IgG antibody
(A11012; Invitrogen) diluted 1:100 in blocking buffer. After
washing, the slides were mounted with ProlongH Gold antifade
reagent containing DAPI (Invitrogen). Immunofluorescence
images were captured using a fluorescence microscope (BX51;
Olympus, Tokyo, Japan).
Results
Utilization of HrasG12V, SmoM2 and shp53 for the
Induction of HCC
Deregulation of Ras, hedgehog, and p53 signaling pathways is
known to be highly related to HCC development in humans. We
attempted to develop simple non-germline liver-specific transgenic
mouse models in which Ras, hedgehog, and p53 signaling
pathways are deregulated, either alone or in combination.
Plasmids encoding a constitutively active form of Hras
(HrasG12V), a constitutively active form of Smo (SmoM2), and
a small hairpin RNA that downregulates TP53 (shp53) were used
to deregulate these signaling pathways in this study. The
expression cassettes encoding each gene were subsequently placed
between two IRs (Fig. 1), rendering them transposable by the
Sleeping Beauty transposase.
To test the expression and biological functions of the genes
expressed from the transposons, transient transfection was
conducted using NIH3T3 cells. Phosphorylation of the down-
stream Ras pathway molecules Akt, MEK, and ERK was
dramatically increased in cells transfected with pT2/HrasG12V
Figure 2. Assessment of the biological functions of HrasG12V, SmoM2, and shp53. (A) Activation of Ras signaling by HrasG12V was
confirmed by increased phosphorylation of Akt, ERK, and MEK. (B) Increased activity of Gli transcription factors in response to expression of SmoM2
was detected using a Gli-driven luciferase reporter system. (C) UV-induced expression of p53 was suppressed by shp53 expression. Cells were
transfected with either pT2/EGFP (a control) or pT2/shp53 prior to UV irradiation.
doi:10.1371/journal.pone.0059869.g002
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compared to cells transfected with pT2/EGFP, confirming the
constitutive activation of Ras signaling by HrasG12V (Fig. 2A).
Activation of hedgehog signaling by SmoM2 was confirmed by
Gli-luciferase reporter assay. Luciferase expression driven by Gli
transcription factors was higher in cells transfected with pT2/
SmoM2 compared to cells transfected with pT2/EGFP (p,0.01,
see Fig. 2B). Lastly, downregulation of p53 expression by pT2/
shp53 was confirmed in an experiment in which p53 expression
was induced by UV irradiation (Fig. 2C).
Figure 3. Co-expression of HrasG12V and shp53 induced malignant tumors in the liver. (A) Strong bioluminescence signals were detected
in the livers of mice co-expressing HrasG12V and shp53, while other double-transgenic mice revealed no detectable signals. BLI was performed at 4
weeks PHI. (B) Gross morphology of mice of the HrasG12V plus shp53 group at 4 weeks PHI. (C) H&E staining of liver tissues from HrasG12V plus
SmoM2 mice (harvested at 30 weeks PHI), HrasG12V plus shp53 mice (harvested at 4 weeks PHI), and SmoM2 plus shp53 mice (harvested at 30 weeks
PHI). (D) Immunofluorescence imaging of Ras. Ras expression was detected in tumors induced by HrasG12V and shp53 (upper right panel), while
normal liver tissues exhibited background signals (lower right panel). DAPI staining of the same region is shown in the panels to the left. Scale bar,
200 mm.
doi:10.1371/journal.pone.0059869.g003
Table 1. Effects of expressed oncogenes on the induction of liver tumors.
Oncogene(s) expressed % of mice with tumors Survival (weeks PHI) Number of nodules
HrasG12V 0 (0/6) .30 None
SmoM2 0 (0/5) .30 None
shp53 0 (0/5) .30 None
HrasG12V, SmoM2 0 (0/8) .30 None
HrasG12V, shp53 100 (8/8) ,5 Too many to count
SmoM2, shp53 0 (0/8) .30 None
doi:10.1371/journal.pone.0059869.t001
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Hydrodynamic Injection of Oncogene-encoding
Transposons and BLI of the Liver
To generate liver-specific transgenic mouse models, transposons
encoding each oncogene were mixed with plasmids encoding the
Sleeping Beauty transposase (pT2/C-Luc//PGK-SB13) and were
then hydrodynamically delivered to the liver (Fig. 1). Once
entering a cell, Sleeping Beauty transposase can integrate transposons
into the genome [24], allowing the transgene to be stably
expressed. The plasmid pT2/C-Luc//PGK-SB13 harbors trans-
Figure 4. Repeated BLI of the same mice following hydrodynamic injection. (A) Pseudocolor images of tumor growth in the liver following
hydrodynamic injection of HrasG12V and shp53. Note the continuous increases in the signals from the abdominal regions of the same mice. (B)
Average bioluminescence signals from the abdominal regions of the same mice at the indicated time points PHI.
doi:10.1371/journal.pone.0059869.g004
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posons encoding firefly luciferase, chromosomal integration of
which allows tumor growth to be monitored by BLI. To generate
transgenic mice expressing a combination of two oncogenes, a
mixture of pT2/HrasG12V plus pT2/SmoM2, pT2/HrasG12V
plus pT2/shp53, or pT2/SmoM2 plus pT2/shp53 was hydrody-
namically delivered to the liver together with pT2/C-Luc//PGK-
SB13 (Table 1). At 4 days post-hydrodynamic injection (PHI), BLI
was performed to confirm successful delivery of plasmid DNA to
the liver. Strong BLI signals were observed in all groups; there
were no significant differences between groups (see Fig. S1). The
strengths of the BLI signals were much lower the following week in
all groups, presumably due to the degradation of unintegrated
plasmids, consistent with previous reports [25,26]. At 4 weeks PHI,
BLI was performed again and very strong signals were detected in
mice in the HrasG12V plus shp53 transgenic group (Fig. 3A). By
contrast, only background signals were detected in the HrasG12V
plus SmoM2, SmoM2 plus shp53, and single-transgenic groups.
The HrasG12V and shp53 double-transgenic mice were subse-
quently euthanized due to signs of discomfort. For the other
groups of mice, BLI experiments were performed every month for
up to 7 months PHI. No significant increases in BLI signals were
observed in the groups (data not shown).
Tumor Incidence and Histology
Mice transfected with HrasG12V and shp53 became moribund
and exhibited signs of discomfort at about 4 weeks PHI. Livers
were harvested from the mice after euthanasia. Tumors were
observed in the livers of all mice in this group (Fig. 3B). H&E
staining showed highly malignant and undifferentiated tumor cells
(Fig. 3C, middle panels). Immunofluorescence imaging confirmed
Ras expression in tumors induced by HrasG12V and shp53
(Fig. 3D). No hyperplastic nodules were observed in other double-
transgenic groups or the single-transgenic groups when livers were
harvested at 7 months PHI. H&E staining also revealed no
microscopic nodules in these groups (Fig. 3C, upper and lower
Figure 5. Tumors in the livers of HrasG12V plus shp53 mice following hydrodynamic injection. (A) Gross morphology of livers harvested
at 1, 2, 3, and 4 weeks PHI. Note that the tumors grew more rapidly in the right lobes. (B) H&E staining of left caudal lobes harvested at the indicated
time points. Scale bar, 200 mm.
doi:10.1371/journal.pone.0059869.g005
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panels). Tumor incidence and mouse survival data are shown in
Table 1.
Correlation between Tumor Size and BLI Signal Intensity
in Tumors Induced by HrasG12V and shp53
To test the correlation between tumor size and BLI signal
intensity in tumors induced by HrasG12V and shp53, we
measured BLI signals at 2, 3, 3.5, and 4 weeks PHI. To
completely remove signals from unintegrated transposons encod-
ing firefly luciferase, we started BLI experiments at 2 weeks PHI
[25]. Repeated imaging of the same mice over time revealed
increases in BLI signals in all mice (Fig. 4A). The increases were
most noticeable between 3 and 3.5 weeks PHI. The average
bioluminescence signal at each time point is shown in Fig. 4B.
To analyze the relationship between BLI signal and tumor
burden in the liver, we harvested livers at 1, 2, 3 and 4 weeks PHI
and investigated tumor sizes. Based on gross morphology,
hyperplastic nodules in the right lobes of the liver were noticed
as early as 2 weeks PHI (Fig. 5A). Tumors grew more slowly in the
left caudal lobes than in the right lobes. Consistent with the gross
morphology, H&E staining of liver tissues in the left caudal lobes
revealed increases in tumor size and tissue invasion (Fig. 5B). The
results strongly suggest that increases in BLI signals can be a strong
indicator of tumor growth in the liver. Thus, tumor growth can be
monitored over time in our transgenic model system based on BLI
signals, without invasive procedures.
Oncogenic Collaboration with c-myc
Expression of HrasG12V, SmoM2, or shp53 alone failed to
induce hepatic tumors in our study. Thus, it is presumed that
expression of at least two oncogenes is required to efficiently
induce tumors in the liver, as shown in the HrasG12V plus shp53
group. It is not clear why SmoM2 failed to induce hepatic tumors
Figure 6. Differential tumorigenic potentials among HrasG12V, SmoM2, and shp53 in the liver. Transposons encoding each oncogene
was mixed with c-myc-encoding transposons and then hydrodynamically delivered to the liver. Gross morphology (A) and H&E staining (B) of livers in
each group are shown. Note that livers were harvested from c-myc plus HrasG12V mice at 2 months PHI, while livers were harvested in the other
groups at 7 months PHI. No hyperplastic nodules were observed in the livers of c-myc plus SmoM2 mice. Scale bar, 200 mm.
doi:10.1371/journal.pone.0059869.g006
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when co-expressed with HrasG12V or shp53 (Fig. 3). One possible
explanation is that cooperation of hedgehog signaling with Ras or
p53 signaling is not as effective as oncogenic collaboration between
Ras and p53 signaling. It is also possible that SmoM2 might be less
oncogenic in the liver compared to HrasG12V or shp53. In this
regard, we tested the hepatocarcinogenic potential of each
oncogene in the liver where c-myc is overexpressed. The c-myc
is known to play an important role in hepatocarcinogenesis and
often overexpressed in human liver cancers. Transposons encod-
ing c-myc (referred to as ‘‘pT2/c-myc’’) was mixed with each of
pT2/HrasG12V, pT2/SmoM2, and pT2/shp53 and then each
combination of oncogenes was hydrodynamically delivered to the
liver together with transposase-encoding plasmids (see Method S1
for the detailed method). Tumors were found in the c-myc plus
HrasG12V group as early as at 2 months PHI and in the c-myc
plus shp53 group at about 7 months PHI (Figure 6). However, no
hyperplastic nodules were observed until 7 months PHI in the c-
myc plus SmoM2 group. This data also supports the idea that
SmoM2 might be less oncogenic than HrasG12V or shp53 in the
liver.
Removing the Transposase Reduces the Numbers of
Hyperplastic Nodules
The liver tumors induced by HrasG12V and shp53 exhibited
numerous hyperplastic nodules. For some applications, such as
efficacy testing of anti-cancer drugs, it might be desirable to use a
tumor model with fewer hyperplastic nodules. For this reason, we
transfected the liver with a mixture of pT2/HrasG12V and pT2/
shp53, without plasmids encoding Sleeping Beauty transposase.
Under these conditions, chromosomal integration of the trans-
genes solely relies on a spontaneous process [27]. Two of five mice
showed signs of discomfort at 3 months PHI and a few large
hyperplastic nodules were found in their livers (Fig. 7A and B).
Thus, removing the Sleeping Beauty transposase greatly reduced the
numbers of hyperplastic nodules. The other three mice, however,
did not show visible hyperplastic nodules when their livers were
harvested at 9 months PHI. This is a potential problem in
preclinical testing of anti-cancer drugs. Rather than completely
removing plasmids encoding Sleeping Beauty transposase, using a
minimal dose of the plasmids might be an option to induce tumors
in all mice while still keeping the numbers of tumor nodules low.
Figure 7. Tumors induced by transposon vectors encoding HrasG12V and shp53 without the Sleeping Beauty transposase. (A) A few
large hyperplastic nodules were observed at 3 months PHI. (B) H&E staining of the tumors shown in (A). Scale bar, 200 mm.
doi:10.1371/journal.pone.0059869.g007
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Discussion
In this study, we presented a simplified methodology with which
the tumorigenic potential of individual genes and combinations of
genes can easily be tested in the liver in vivo. First, we generated
non-germline liver-specific transgenic mouse models more quickly
and cheaply using hydrodynamics-based transfection and the
Sleeping Beauty transposon system. Second, we utilized firefly
luciferase as a reporter, allowing tumor growth in the liver to be
easily monitored via BLI without an invasive procedure. Appli-
cation of the methodology is expected to accelerate and facilitate
in vivo studies of the oncogenic potential of cancer-related genes in
the liver. Although the methodology is considered versatile and
cost-effective in generating transgenic models for liver cancer and
monitoring tumor growth, there are some potential disadvantages
of the method. Because transgenic mouse developed by hydrody-
namic injection cannot transmit transgenes to offspring, DNA
injection should be performed for each tumorigenic study.
Furthermore, due to a high volume of solution injected rapidly
via the tail vein, liver might experience a mechanical injury after
DNA injection although hydrodynamic injection is generally
considered to cause little harm [28].
Using this strategy, we tested the oncogenic potential of
HrasG12V, SmoM2, and shp53 in the liver. Mice with
simultaneous expression of HrasG12V and shp53 in the liver
exhibited very strong BLI signals in the abdominal area.
Consistent with the BLI data, gross morphology revealed rapidly
induced tumors in the liver with numerous hyperplastic nodules.
Tumors in this group were also highly malignant and poorly
differentiated (Fig. 3C). Expression of either HrasG12V or shp53
alone, however, failed to induce hepatic tumors in our study.
Thus, it is presumed that both proliferation and anti-apoptotic
signals are required to efficiently induce tumors in the liver.
Simultaneous expression of HrasG12V plus SmoM2 or SmoM2
plus shp53 also failed to induce tumors in the liver. The reason
why tumors were not observed in the other double transgenic mice
is unclear. SmoM2 induces activation of hedgehog signaling,
leading to cellular proliferation in many tissues [9,10]. One
possible explanation is that SmoM2 might be less oncogenic in the
liver compared to HrasG12V or shp53. We further tested the
hepatocarcinogenic potential of SmoM2 via co-expression with c-
myc. No hyperplastic nodules were observed in the livers of c-myc
plus SmoM2 mice until 7 months PHI while tumors were observed
both in the c-myc plus HrasG12V and c-myc plus shp53 groups.
This also suggests that SmoM2 is less oncogenic than HrasG12V
or shp53 in the liver. Although SmoM2 failed to cooperate with
HrasG12V, shp53, and c-myc in inducing hepatic tumors,
however, we cannot rule out the possibility that SmoM2 could
induce hepatic tumors via oncogenic collaboration with other
types of oncogenes. More extensive studies should be performed to
address this issue.
Due to the difficulty of accessing the liver, liver tumor sizes are
hard to measure without invasive surgery or killing the animal.
Imaging techniques such as micro-computed tomography and
micro-positron emission tomography have been developed to
detect tumor lesions and to quantify tumor load in small animals
[29]. Although recent years have seen refinements and advances in
imaging techniques, they are still not easily accessible to many
researchers due to the high cost of imaging instruments and
technical difficulties. Optical imaging techniques such as fluores-
cence imaging and BLI are, however, cost effective and relatively
easy to use [30,31]. Firefly luciferase was successfully utilized in
our study to monitor changes in tumor sizes in vivo. Increases in
BLI signals were well correlated with actual tumor growth in the
liver in our transgenic mouse model, confirming the versatility of
BLI in monitoring tumor growth without an invasive procedure.
One important application of our model system is preclinical
testing of therapeutic drugs for liver cancer. Retardation of tumor
growth or reduction of tumor size could be effectively monitored
by repeated BLI over time following drug administration.
Currently, we are applying the transgenic model to study the
anti-cancer effects of Akt inhibitors and dietary intervention
(manuscript in preparation). It is expected that the applicability of
the transgenic liver cancer model will broaden because of the ease
of development of the tumor model and efficient in vivo imaging of
tumor growth.
Supporting Information
Figure S1 Bioluminescence imaging performed at 4
days post hydrodynamic injection. Strong bioluminescence
signals were observed from the livers of all mice, confirming
successful delivery of transgenes to the liver. No significant
differences in bioluminescence signals were found among the
double transgenic groups. Similar results were obtained from the
single transgenic groups (data not shown).
(TIF)
Method S1 Hydrodynamic injection of c-myc-encoding
transposons.
(DOC)
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